Effects of Gender-Affirming Hormones on Lipid, Metabolic, and Cardiac Surrogate Blood Markers in Transgender Persons | Zendy

Justine Defreyne | Zendy; Laurens D L Van de Bruaene | Zendy; Ernst Rietzschel | Zendy; Judith Van Schuylenbergh | Zendy; Guy T’Sjoen | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Effects of Gender-Affirming Hormones on Lipid, Metabolic, and Cardiac Surrogate Blood Markers in Transgender Persons

Author(s) -

Justine Defreyne,

Laurens D L Van de Bruaene,

Ernst Rietzschel,

Judith Van Schuylenbergh,

Guy T’Sjoen

Publication year - 2019

Publication title -

clinical chemistry

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.705

H-Index - 218

eISSN - 1530-8561

pISSN - 0009-9147

DOI - 10.1373/clinchem.2018.288241

Subject(s) - transgender , medicine , hormone therapy , testosterone (patch) , transgender women , prospective cohort study , gynecology , gerontology , psychology , men who have sex with men , family medicine , breast cancer , cancer , human immunodeficiency virus (hiv) , psychoanalysis , syphilis

Gender-affirming hormonal therapy consists of testosterone in transgender men and estrogens and antiandrogens in transgender women. Research has concluded that gender-affirming therapy generally leads to high satisfaction rates, increased quality of life, and higher psychological well-being. However, given the higher incidence of cardiometabolic morbidity and mortality in cisgender men compared with cisgender women, concerns about the cardiometabolic risk of androgen therapy have been raised.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research